{"id":"gazyvaro","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Gazyva®","Obinutuzumab"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"B-lymphocyte antigen CD20"},"_scrapedAt":"2026-03-28T06:06:08.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"CD20-positive follicular lymphoma","diseaseId":"cd20-positive-follicular-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic lymphoid leukemia, disease","diseaseId":"chronic-lymphoid-leukemia-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06192888","phase":"PHASE1","title":"A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-01-08","conditions":"Mantle Cell Lymphoma, MCL","enrollment":39},{"nctId":"NCT03824483","phase":"PHASE2","title":"Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-02-22","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)","enrollment":230},{"nctId":"NCT03701282","phase":"PHASE3","title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":720},{"nctId":"NCT03223610","phase":"PHASE1, PHASE2","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-09","conditions":"Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":155},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":73},{"nctId":"NCT04269902","phase":"PHASE3","title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-02","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":247},{"nctId":"NCT06649812","phase":"PHASE2","title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-10-07","conditions":"High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","enrollment":120},{"nctId":"NCT03737981","phase":"PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":465},{"nctId":"NCT05896163","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-08-30","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT04277637","phase":"PHASE1","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2020-03-24","conditions":"Mature B-Cell Malignancies","enrollment":437},{"nctId":"NCT06793189","phase":"PHASE2","title":"MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-23","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":145},{"nctId":"NCT07003295","phase":"PHASE2","title":"Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-14","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":20},{"nctId":"NCT06994468","phase":"NA","title":"Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-09-22","conditions":"Membranous Nephropathy","enrollment":48},{"nctId":"NCT06073821","phase":"PHASE3","title":"Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-11-11","conditions":"CLL","enrollment":652},{"nctId":"NCT06943872","phase":"PHASE3","title":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-06-11","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":630},{"nctId":"NCT05169515","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-26","conditions":"Non-Hodgkin Lymphoma","enrollment":121},{"nctId":"NCT07480863","phase":"PHASE2","title":"Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-01","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":65},{"nctId":"NCT07480850","phase":"PHASE2","title":"Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":40},{"nctId":"NCT06561360","phase":"PHASE2","title":"A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-09","conditions":"Hairy Cell Leukemia","enrollment":86},{"nctId":"NCT06634589","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2024-11-27","conditions":"B-cell Malignancy, Relapsed Cancer, Refractory Cancer","enrollment":80},{"nctId":"NCT04889716","phase":"PHASE2","title":"CAR-T Followed by Bispecific Antibodies","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-11-05","conditions":"Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":42},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT05478512","phase":"PHASE2","title":"Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2023-07-21","conditions":"High Risk CLL, Chronic Lymphocytic Leukemia","enrollment":78},{"nctId":"NCT05783596","phase":"PHASE2","title":"Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Reid Merryman, MD","startDate":"2023-07-18","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma","enrollment":47},{"nctId":"NCT04703686","phase":"PHASE2","title":"Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-30","conditions":"Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma","enrollment":67},{"nctId":"NCT07218510","phase":"PHASE2","title":"Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-07","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":33},{"nctId":"NCT04970901","phase":"PHASE1","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","status":"RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2022-06-17","conditions":"B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT03462719","phase":"PHASE3","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-17","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":211},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT02629809","phase":"PHASE2","title":"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-03-18","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":81},{"nctId":"NCT06940661","phase":"PHASE2","title":"Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-19","conditions":"Granulomatosis With Polyangiitis","enrollment":33},{"nctId":"NCT03075696","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-02-21","conditions":"Non-Hodgkin's Lymphoma","enrollment":940},{"nctId":"NCT06090539","phase":"PHASE1, PHASE2","title":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-12-29","conditions":"Relapsed/Refractory Non-Hodgkin Lymphoma","enrollment":308},{"nctId":"NCT07453095","phase":"PHASE2","title":"Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-04-15","conditions":"Mantle Cell Lymphoma","enrollment":41},{"nctId":"NCT06624085","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-28","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT07441954","phase":"PHASE1, PHASE2","title":"Pomalidomide Combined With Obinutuzumab in the Treatment of Patients With Relapsed/Refractory Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-20","conditions":"Indolent Lymphoma","enrollment":53},{"nctId":"NCT04077723","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-13","conditions":"Lymphoma, Non-Hodgkin","enrollment":498},{"nctId":"NCT06806033","phase":"PHASE2","title":"A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-03-05","conditions":"B-Cell Non-Hodgkins Lymphoma","enrollment":100},{"nctId":"NCT06504940","phase":"PHASE2","title":"Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-28","conditions":"Marginal Zone Lymphoma","enrollment":69},{"nctId":"NCT05650723","phase":"PHASE2","title":"Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell","enrollment":50},{"nctId":"NCT04739813","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-09","conditions":"Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":55},{"nctId":"NCT04169737","phase":"PHASE2","title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-29","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":168},{"nctId":"NCT05536349","phase":"PHASE2","title":"Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-12-20","conditions":"Leukemia","enrollment":60},{"nctId":"NCT06651970","phase":"PHASE4","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukaemia, Heart Failure","enrollment":60},{"nctId":"NCT02867384","phase":"PHASE2","title":"Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-11-29","conditions":"Graft vs. Host Disease","enrollment":181},{"nctId":"NCT05336812","phase":"PHASE2","title":"Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2022-09-13","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":52},{"nctId":"NCT03930953","phase":"PHASE1, PHASE2","title":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-05-20","conditions":"Lymphoma, Non-Hodgkin","enrollment":438},{"nctId":"NCT03198026","phase":"PHASE2","title":"Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2018-02-20","conditions":"Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma","enrollment":30},{"nctId":"NCT05861050","phase":"PHASE1, PHASE2","title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-10","conditions":"Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma","enrollment":50},{"nctId":"NCT03332017","phase":"PHASE2","title":"A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-11-14","conditions":"Relapsed/Refractory Follicular Non-Hodgkin Lymphoma","enrollment":217},{"nctId":"NCT05057494","phase":"PHASE3","title":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-12","conditions":"Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","enrollment":607},{"nctId":"NCT02846623","phase":"PHASE2","title":"Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-01-31","conditions":"Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia","enrollment":50},{"nctId":"NCT03580928","phase":"PHASE2","title":"Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-08-07","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":72},{"nctId":"NCT03410875","phase":"PHASE2","title":"A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-02-09","conditions":"Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell","enrollment":30},{"nctId":"NCT06558604","phase":"PHASE2","title":"Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2025-02-21","conditions":"Lymphoma, Mantle-Cell","enrollment":100},{"nctId":"NCT04895436","phase":"PHASE2","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-03-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":75},{"nctId":"NCT04883437","phase":"PHASE2","title":"Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-09-03","conditions":"Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma","enrollment":49},{"nctId":"NCT03516617","phase":"PHASE2","title":"Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-09-10","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":120},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT07107490","phase":"PHASE1","title":"A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER","status":"RECRUITING","sponsor":"Chugai Pharmaceutical","startDate":"2025-10-08","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":122},{"nctId":"NCT04560322","phase":"PHASE2","title":"Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-10-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT06357676","phase":"PHASE1, PHASE2","title":"Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-05-29","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT02427451","phase":"PHASE1, PHASE2","title":"Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kerry Rogers","startDate":"2015-08-03","conditions":"Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia","enrollment":87},{"nctId":"NCT07233330","phase":"PHASE2","title":"Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2026-02","conditions":"Nephrotic Syndrome，Idiopathic","enrollment":10},{"nctId":"NCT04855695","phase":"PHASE1, PHASE2","title":"Avo In R/R And Previously Untreated MCL","status":"RECRUITING","sponsor":"Austin I Kim","startDate":"2021-07-02","conditions":"Mantle Cell Lymphoma, Refractory Lymphoma","enrollment":72},{"nctId":"NCT07355699","phase":"PHASE4","title":"Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-11-25","conditions":"Marginal Zone Lymphoma(MZL)","enrollment":88},{"nctId":"NCT07024706","phase":"PHASE2","title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-30","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)","enrollment":80},{"nctId":"NCT06781944","phase":"PHASE3","title":"OBINOTUZUMAB Versus Cyclophosphamide + Glucocorticoids in Primary Membranous Nephropathy(Blossom Study)","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-10-23","conditions":"Primary Membranous Nephropathy","enrollment":144},{"nctId":"NCT06333262","phase":"PHASE2","title":"Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Inhye Ahn","startDate":"2024-04-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT02896582","phase":"PHASE2","title":"Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-11-29","conditions":"Mantle Cell Lymphoma","enrollment":86},{"nctId":"NCT06213311","phase":"PHASE2","title":"A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-07","conditions":"B Cell Lymphoma","enrollment":40},{"nctId":"NCT07326371","phase":"PHASE2","title":"Glofitamab Combined With CAR-T Therapy in R/R DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":24},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS","enrollment":14},{"nctId":"NCT06291220","phase":"PHASE1","title":"A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2025-01-27","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":4},{"nctId":"NCT04963296","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-26","conditions":"Systemic Lupus Erythematosus","enrollment":303},{"nctId":"NCT06043674","phase":"PHASE2","title":"Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2024-01-22","conditions":"Chronic Lymphocytic Leukemia, Richter's Transformation","enrollment":70},{"nctId":"NCT04843904","phase":"PHASE1","title":"Safe Accelerated Venetoclax Escalation in CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-04-14","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT04629248","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Primary Membranous Nephropathy","enrollment":142},{"nctId":"NCT07163611","phase":"PHASE2, PHASE3","title":"Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2025-10-01","conditions":"Membranous Nephropathy - PLA2R Induced","enrollment":20},{"nctId":"NCT07108998","phase":"PHASE2","title":"Study of Epcoritamab as a Consolidation Therapy in CLL/SLL","status":"RECRUITING","sponsor":"Zulfa Omer","startDate":"2025-08-22","conditions":"CLL/SLL, CLL, SLL","enrollment":22},{"nctId":"NCT03533283","phase":"PHASE1, PHASE2","title":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-05-08","conditions":"Non-Hodgkins Lymphoma","enrollment":211},{"nctId":"NCT06054776","phase":"PHASE2","title":"Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-12-02","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT04505254","phase":"PHASE2","title":"Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-25","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT05929222","phase":"PHASE3","title":"Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-12-14","conditions":"Follicular Lymphoma","enrollment":190},{"nctId":"NCT07299149","phase":"PHASE2","title":"Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-25","conditions":"Follicular Lymphoma","enrollment":34},{"nctId":"NCT02296918","phase":"PHASE1","title":"Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-12-22","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia","enrollment":69},{"nctId":"NCT06108232","phase":"PHASE2","title":"Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-15","conditions":"Follicular Lymphoma, Tumor","enrollment":36},{"nctId":"NCT07165769","phase":"PHASE2","title":"Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-04","conditions":"Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN","enrollment":47},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":85},{"nctId":"NCT06186648","phase":"PHASE2","title":"Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome","status":"RECRUITING","sponsor":"French Innovative Leukemia Organisation","startDate":"2024-03-21","conditions":"Richter Syndrome","enrollment":40},{"nctId":"NCT06265220","phase":"PHASE1","title":"AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2024-04-03","conditions":"Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus","enrollment":51},{"nctId":"NCT03342144","phase":"","title":"Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting","status":"RECRUITING","sponsor":"AbbVie","startDate":"2017-12-04","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":500},{"nctId":"NCT07268521","phase":"PHASE2","title":"A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-01","conditions":"Cryoglobulinemic Vasculitis (CV)","enrollment":30},{"nctId":"NCT07261163","phase":"PHASE2","title":"Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-20","conditions":"Mantle Cell Lymphoma","enrollment":37},{"nctId":"NCT06824701","phase":"PHASE1","title":"Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Utah","startDate":"2025-09-12","conditions":"Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":5,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_1","status":"active","brandName":"Gazyvaro","genericName":"Gazyvaro","companyName":"Incyte Corporation","companyId":"incyte","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":87,"withResults":12},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}